 |
BioWorld-Insight-2002-04-01
Would-Be Competitors Eye Amgen's EPO Market Lock-Up
Would-Be Competitors Eye Amgen's EPO Market Lock-Up
You might not expect onlookers to be especially sanguine about competitors against erythropoietin king Amgen Inc., which continues to reap revenues galore from its blood-boosting blockbuster drug. Last week, though, two companies with EPO ambitions made news. (BioWorld Financial Watch)
Biotech - Biotech Collaborations: Modified And Terminated Agreements, Jan. 1 - March 25, 2002#
No Abstract